	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	1,620	2,044	2,633	3,463	4,401	3,625	5,665	5,617	6,431
Cost of Operating Revenue	760	965	1,231	1,637	2,260	1,880	2,576	2,517	2,667
Gross Profit	860	1,079	1,402	1,826	2,141	1,745	3,089	3,100	3,764
Gross Margin	53.1	52.8	53.3	52.7	48.7	48.1	54.5	55.2	58.5
Total Operating Expenses	1,121	1,420	1,772	2,259	3,001	2,740	4,676	4,724	5,225
Operating Profit	499	624	861	1,203	1,400	884	989	893	1,206
Operating Margin	30.8	30.5	32.7	34.8	31.8	24.4	17.5	15.9	18.8
Financing Income/(Expense) - Net	44	81	114	123	216	232	135	164	-33
Profit before Taxes	501	686	993	1,335	1,619	1,055	1,133	1,063	1,465
Income Taxes	180	234	220	338	407	274	360	364	437
Profit after Tax	321	452	773	997	1,212	781	772	699	1,027
PAT Margin	19.8	22.1	29.4	28.8	27.5	21.5	13.6	12.4	16.0
EPS - Basic - ex Extraordinary Items	19.66	27.67	47.33	63.07	73.81	47.44	46.90	42.40	62.35
EPS - Diluted - ex Extraordinary Items	19.66	27.67	47.33	62.99	73.64	47.43	46.89	42.40	62.28
EBIT	499	624	861	1,203	1,400	884	989	893	1,206
EBITDA	578	706	955	1,302	1,510	1,031	1,333	1,271	1,630
EBITDA Margin	35.7	34.6	36.3	37.6	34.3	28.4	23.5	22.6	25.3

Balance Sheet

Abridged

Understanding Balance Sheet

Gland Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	1,732	2,357	2,846	5,124	5,852	6,901	5,645	6,783	7,527
Long-Term Investments	-	-	-	-	-	-	655	-	-
Property Plant & Equipment - Net	1,043	1,053	1,157	1,292	1,680	1,736	3,830	3,944	4,432
Total Non-Current Assets	1,197	1,166	1,240	1,372	1,982	1,877	5,016	4,442	4,984
Total Assets	2,929	3,524	4,086	6,496	7,834	8,778	10,661	11,225	12,511
Total Current Liabilities	379	533	359	513	582	729	1,398	1,565	1,608
Long Term Debt	7	6	5	5	4	4	141	107	93
Total Non-Current Liabilities	140	129	81	80	94	90	539	509	544
Total Liabilities	519	662	440	593	676	819	1,937	2,074	2,153
Total Shareholders' Equity	2,410	2,862	3,646	5,903	7,158	7,959	8,724	9,151	10,358
Total Equity	2,410	2,862	3,646	5,903	7,158	7,959	8,724	9,151	10,358
Total Liabilities & Equity	2,929	3,524	4,086	6,496	7,834	8,778	10,661	11,225	12,511

Cash Flow

Abridged

Understanding Cash Flow Statement

Gland Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	417	576	818	1,100	1,311	936	1,161	1,047	1,486
Working Capital - Increase/(Decrease)	-193	-354	-80	-436	-393	-418	-53	-6	-254
Net CF from Operating Activities	223	222	738	665	918	518	1,108	1,041	1,231
Capital Expenditures - Net	85	135	171	228	522	223	397	394	494
Net CF from Investing Activities	-383	-354	-810	-1,586	-1,133	1,048	-1,894	1,548	-95
Dividends Paid - Cash - Total	-	-	-	-	-	-	-	329	297
Stock - Issuance/(Retirement) - Net	-	-	-	1,242	39	21	1	2	-
Debt - LT & ST - Issuance/(Retirement) - Total	-1	-1	-1	-1	0	0	-774	-76	-88
Net Cash Flow from Financing Activities	-1	-1	-1	1,241	38	21	-774	-403	-385
Free Cash Flow to Equity	138	87	567	435	396	295	-64	571	649
Free Operating CF net dividend	138	87	543	436	396	295	710	317	440
Free Operating CF	138	87	543	436	396	295	710	646	737

Business Segment Analysis

FY End:

Mar 25

Gland Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 394.17 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 5,616.50 Cr

Assets

Pharmaceuticals (100.0%)₹ 11,224.92 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 892.91 Cr

Regional Segment Analysis

FY End:

Mar 25

Gland Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

USA (48.7%)₹ 2,740.33 CrRest of World (ROW) (20.2%)₹ 1,137.70 CrEurope (18.2%)₹ 1,022.51 CrIndia (8.5%)₹ 476.52 CrCanada (2.8%)₹ 157.43 CrAustralia (1.3%)₹ 74.29 CrNew Zealand (0.1%)₹ 7.72 CrNew Zealand (0.1%)₹ 7.72 Cr

Historical Segment Analysis

Track how Gland Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	229	522	223	398	394

Frequently Asked Questions

What is the revenue of Gland Pharma Ltd.?

The latest trailing twelve month revenue of Gland Pharma Ltd. is ₹ 6,430.65 Cr, reflecting a 1-year growth of 14.50% and a 3-year CAGR of 21.06%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Gland Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Gland Pharma Ltd. is ₹ 1,027.32 Cr, with a 3-year earnings CAGR of 9.51%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Gland Pharma Ltd.?

The trailing twelve month EBITDA of Gland Pharma Ltd. is approximately ₹ 1,205.88 Cr (based on an operating margin of 18.75%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Gland Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Gland Pharma Ltd. is 62.28. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Gland Pharma Ltd.?

The debt-to-equity ratio of Gland Pharma Ltd. stands at 0.03. The interest coverage ratio is 36.24x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Gland Pharma Ltd.?

The estimated book value per share of Gland Pharma Ltd. is 632.04 (derived from a P/B ratio of 3.90 and market price of ₹ 2,462.30), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Gland Pharma Ltd.?

The trailing twelve month operating cash flow of Gland Pharma Ltd. is ₹ 1,231.29 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Gland Pharma Ltd. report consolidated or standalone financials?

Gland Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.